The expression and function of a new cytokine-induced endothelial cell adhesion protein, vascular cell adhesion molecule-I (VCAM-1 ), was characterized in vitro by using a monoclonal antibody, MoAb 4B9, which recognizes a functional epitope on this protein. As determined by enzymelinked immunosorbent assay and radioimmunoprecipitation of metabolically labeled cells, VCAM-1 was minimally expressed on unstimulated human umbilical vein endothelium (HUVE), but was rapidly induced by recombinant human tumor necrosis factor-a (rhTNF-a), rh interleukin-I , and lipopolysaccharide. In contrast to intercellular adhesion molecule-I, VCAM-1 was not induced on dermal fibroblasts or arterial smooth muscle cells after stimulation H E ADHERENCE of circulating lymphocytes to vascu-T lar endothelium is a critical event in the evolution of the inflammatory and immune response. Surface proteins on both lymphocytes and endothelial cells are involved in this adhesive interaction.' The binding of lymphocyte functionassociated antigen-1, LFA-1 (CDl la/CD18), on lymphocytes* to intercellular adhesion molecule-1, (ICAM-1, CD54),3 on endothelial cells accounts for a significant portion of the binding of lymphocytes to cultured human endothelium. However, the interaction of LFA-1 with ICAM-I is only one of several potential mechanisms by which lymphocytes adhere to vascular e n d~t h e l i u m .~.~ Recently, using an expression-cloning technique, Osborn et aI6 identified a novel protein that is induced on human umbilical vein endothelium (HUVE) by tumor necrosis factor (TNF-a) and interleukin-1 (IL-1) and is involved in adherence of lymphocytic cell lines. This inducible endothelial adhesion protein has been designated vascular cell adhesion molecule-1 (VCAM-1). Independently, we generated a monoclonal antibody, MoAb 4B9, to recombinant human (rh) TNF-stimulated HUVE that inhibited the binding of several lymphocytic cell lines.
The expression and function of a new cytokine-induced endothelial cell adhesion protein, vascular cell adhesion molecule-I (VCAM-1 ), was characterized in vitro by using a monoclonal antibody, MoAb 4B9, which recognizes a functional epitope on this protein. As determined by enzymelinked immunosorbent assay and radioimmunoprecipitation of metabolically labeled cells, VCAM-1 was minimally expressed on unstimulated human umbilical vein endothelium (HUVE), but was rapidly induced by recombinant human tumor necrosis factor-a (rhTNF-a), rh interleukin-I , and lipopolysaccharide. In contrast to intercellular adhesion molecule-I, VCAM-1 was not induced on dermal fibroblasts or arterial smooth muscle cells after stimulation H E ADHERENCE of circulating lymphocytes to vascu-T lar endothelium is a critical event in the evolution of the inflammatory and immune response. Surface proteins on both lymphocytes and endothelial cells are involved in this adhesive interaction. ' The binding of lymphocyte functionassociated antigen-1, LFA-1 (CDl la/CD18), on lymphocytes* to intercellular adhesion molecule-1, (ICAM-1, CD54),3 on endothelial cells accounts for a significant portion of the binding of lymphocytes to cultured human endothelium. However, the interaction of LFA-1 with ICAM-I is only one of several potential mechanisms by which lymphocytes adhere to vascular e n d~t h e l i u m .~.~ Recently, using an expression-cloning technique, Osborn et aI6 identified a novel protein that is induced on human umbilical vein endothelium (HUVE) by tumor necrosis factor (TNF-a) and interleukin-1 (IL-1) and is involved in adherence of lymphocytic cell lines. This inducible endothelial adhesion protein has been designated vascular cell adhesion molecule-1 (VCAM-1). Independently, we generated a monoclonal antibody, MoAb 4B9, to recombinant human (rh) TNF-stimulated HUVE that inhibited the binding of several lymphocytic cell lines.
In this report we characterize the surface expression and adhesive function of VCAM-1. We demonstrate that MoAb 4B9 binds to transfected Chinese hamster ovary (CHO) cells stably expressing VCAM-1, but not to untransfected C H O cells or to C H O cells transfected with ICAM-1 or ELAM-1 cDNA. VCAM-1 is induced on HUVE by rhTNF-a, as well as by lipopolysaccharide (LPS) or rhIL-1, with kinetics of induction similar to that reported for ICAM-1.' However, VCAM-1 differs from ICAM-1 in the pattern of cytokines that induce it and in the cells in which it can be induced. Finally, .we show that MoAb 4B9 significantly inhibits the CD 18-independent component of the adherence of peripheral blood lymphocytes (PBL) and lymphocytic cell lines to rhTNF-stimulated HUVE. polylinker sequence. The resulting plasmid, pBG341, was cleaved by Not1 and Aat2. The smaller of the two fragments was ligated to the larger of the two fragments generated by Notl and Aat2 cleavage of vector pJOD-S? The resulting vector pBG341JOD contains an expression cassette for the dihydrofolate reductase cDNA gene" and a unique Notl site downstream from the adenovirus major late promoter. CHO cells stably expressing ICAM-I were a gift from Barbara Wallner (Biogen, Inc, Cambridge, MA). The animal cell vector pBG368 was used to generate a vector for the insertion of ICAM-1 cDNA that was provided by Dr Brian Seed." The cDNA sequences for either ELAM-l,'* VCAM-1,6 or ICAM-I" were inserted into the vector Notl site to generate the animal cell expression vectors pBG341 JOD.ELAM and .VCAM, pBG368JOD.ICAM, respectively.
MATERIALS AND METHODS

Generation
To generate cell lines stably expressing ELAM-1, VCAM-1, and ICAM-I, CHO-DHFR cells'3 were electroporated with 20 pg pBG341 JOD.ELAM or .VCAM, or pBG368JOD.ICAM as described.' Before electroporation the plasmid was linearized using Aat2. After transfection the cells were cultured in selective medium (MEM alpha minus, GIBCO, Grand Island, NY) lacking ribonucleosides and deoxynuclmtides, supplemented with 500 nmol/L methotrexate, 4 nmol/L glutamine, and 10% dialyzed fetal bovine serum (FBS) to select for methotrexate-resistant cells. Individual colonies were picked, plated into 96-well cluster plates, and grown to confluence. Clones expressing sufficient ELAM-1 or VCAM-1 to bind HL60 cells or Ramos cells, respectively, were detected by 966 CARLOS ET AL adhesion assay as described.'* Clones expressing ICAM-1 were assayed by fluorescence-activated cell sorter (FACS) analysis.
MoAb 4B9, a murine immunoglobulin GI (IgG,), was generated by immunizing BALB/c mice with HUVE that were nonenzymatically harvested after stimulation for 24 hours with rhTNF-a (10 ng/mL). Splenocytes were fused with the NS-I nonsecretory murine myeloma line that was kindly provided by Dr Charles Hart (Zymogenetics, Inc, Seattle, WA). Hybridoma supernatants were screened by enzyme-linked immunosorbent assay (ELISA) for binding to rhTNF-stimulated HUVE versus unstimulated HUVE. A secondary screen assayed the inhibition of adherence of the undifferentiated leukemic cell line KGla. Previous studies had shown that a major portion of the adherence of this cell line to rhTNF-stimulated HUVE was LFA-1-independent. Initial studies used ascites (total IgG 3.2 mg/mL), while later studies used protein A (Pharmacia, Inc, Piscataway, NJ) purified IgG (20 mg/mL). MoAb R R l / l , a well-~haracterized'~ murine IgG, that recognizes ICAM-1, was kindly provided by Dr Robert Rothlein HUVE cells were pretreated with rhTNF-a (10 ng/mL) for 1 hour of incubation at 37OC. The medium was aspirated from all dishes and methionine-free MEM (GIBCO Labs) supplemented with 15% FBS, ECGF/heparin, with or without rhTNF-a (10 ng/mL) was added. Trans-%-label (1 mCi/dish; 1,204 Ci/mmol/L, ICN Biomed Inc, Irvine, CA) was added during a 3-hour incubation at 37OC. The cells were nonenzymatically harvested, and were washed with PBS containing 2 mmol/L phenylmethyl-sulfonylfluoride (PMSF). The cells were lysed overnight at 4OC in phosphate-buffered saline (PBS) containing 0.5% NP-40 and 2 mmol/L PMSF, and centrifuged (12,OOOg x 15 minutes) to remove debris. Cell lysates were precleared with nonimmune mouse IgG (Cappel Research Products, Organon Tecknika Corp, West Chester, PA) and protein A (Pharmacia). Radioimmunoprecipitation of CHO cells stably expressing VCAM-1 was performed using protein G (Pharmacia). The lysates were then incubated for 18 hours with MoAb 4B9 conjugated to Affi-Gel-10 (Bio-Rad Lab, Richmond, CA). Antibody-conjugated beads were pelleted, washed three times with PBS containing 0.1% NP-40, and placed in sample buffer with or without 5% mercaptoethanol. Samples were boiled for 2 minutes, analyzed by 3% to 7% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),I6 and autofluorographed. For N-glycosidase F treatment, immunoprecipitate samples were incubated overnight at 37OC.
rhTNF-a was provided by Biogen, Inc (Cambridge, MA). Lyophilized rh cytokines (TNF-8, IL-1 a / & IL-2, IL-3, IL-4, IL-6, TGF-8) were purchased from Research & Diagnostic Systems, Inc (Minneapolis, MN) and were suspended in sterile distilled water (GIBCO). rhIFN-y was supplied by Genentech, Inc (South San Francisco, CA). Escherichia coli 055:B5 LPS (Sigma Chemical Co, St Louis, MO) was suspended in PBS at a concentration of 1.2 mg/mL, dispersed by sonication for 5 minutes at 4OC, and stored at -35OC. N-glycanase was purchased from Genzyme Corp (Boston, MA). First-or second-passage HUVE were plated onto gelatin-coated 48-well tissue culture plates and allowed to reach confluence. rhTNF-a was added to some of the wells for 24 hours before the assay. The medium was decanted and the wells were washed twice with PBS. Subsequently, 0.2 mL of control medium (RPMI-2% NCS) or medium containing various MoAbs was added for a 30-minute preincubation; the medium was then decanted and 0.2 mL of labeled leukocytes was added to each well. Adherence of PBL or the leukemic cell lines to unstimulated or rhTNF-a-stimulated HUVE was measured as de~cribed.'~ Levels of statistical significance were calculated by paired t-test using Statview + (Brainpower, Inc, Calabasas, CA).
Adherence assay.
RESULTS
T h e specificity of MoAb 4B9 for VCAM-1 was established by a n ELISA screen of untransfected CHO cells and transfected CHO cells stably expressing E L A M -1, VCAM-1, or ICAM-1 (Fig 1A) . MoAb 4B9 reacted only with VCAM-1-transfected CHO cells. MoAb 4B9 immunoprecipitated a protein of approximately 100-Kd cell from lysates of metabolically labeled CHO cells transfected with VCAM-1 c D N A (Fig 1B) .
Unstimulated H U V E were metabolically labeled with 35S-methionine and 35S-cysteine during a 3-hour incubation with medium alone or medium containing r h T N F (10 ng/mL). Cell lysates were immunoprecipitated by M o A b 4B9 and subjected to SDS-PAGE and autofluorography (Fig   2) . Analysis of the radioimmunoprecipitates from rhTNFtreated H U V E showed a major band a t 93 Kd and a minor band a t 80 Kd that migrated at slightly higher molecular weights (100 Kd and 92 Kd) under reducing conditions (Fig   2A) . Analysis of radioimmunoprecipitates from unstimulated H U V E demonstrated only faint bands a t the same molecular weights. After N-glycosidase F treatment of the immunoprecipitate from rhTNF-treated HUVE, a single band was detected a t 80 Kd (Fig 2B) .
T h e expression of VCAM-1 and I C A M -I was measured on rhTNF-stimulated H U V E by E L I S A using M o A b 4B9 and an isotype-matched MoAb, RR 1/1 (Fig 3) . As previously reported,' ICAM-1 was constitutively expressed by untreated HUVE. Surface expression of ICAM-1 peaked after 24 hours of continuous stimulation by r h T N F -a (10 ng/mL), and levels that were greater than basal were maintained for a t least 48 hours. In contrast to the constituitive expression of ICAM-1, little or no VCAM-I was For personal use only. on October 22, 2017. by guest www.bloodjournal.org From when HUVE was treated with IO ng/mL of rhTNF-6.
A series of experiments was performed to determine the rhlL-2. rhlL-3. rhlL-4. rhlL-6. or rhTGF-8 (A,,, < 0.020).
roleof VCAM-I in theadherenceof lymphocyticcell linesor Additionally. treatment of HUVE with rhlFN-y for 24 PRL to HUVE that had been pretreated with rhTNF-a. For Before the adherence assay, HUVE were incubated with control medium, or medium containing MoAb R R 1/1 or MoAb 4B9. 5'Cr-labeled leukocytes were preincubated with either control medium or medium containing MoAb 60.3 The adherence of neutrophils to HUVE that were stimulated for 24 hours with rhTNF-a was also examined. No inhibition of neutrophil adherence to rhTNF-a-stimulated HUVE was observed. Percent adherence to unstimulated HUVE was 2% 1% and adherence to rhTNF-a treated HUVE was 17% k 1% in the absence of MoAb 4B9 and 22% k 2% in the presence of MoAb 4B9 (means k S D of three experiments).
DISCUSSION
Three endothelial proteins have previously been reported to be involved in leukocyte adhesion to endothelium in humans: endothelial cell adhesion molecule-1 (ELAM-l), PADGEM (GMP-140, CD62), and ICAM-1.2,'8 Functional characterization of VCAM-1 demonstrates that it shares properties that have been reported for both ELAM-1 and ICAM-1. Like ELAM-1,I9 VCAM-1 was not expressed or was minimally expressed on unstimulated endothelium, but was rapidly induced by LPS, rhTNF-a, or rhIL-1. However, VCAM-1 is functionally distinct from ELAM-1 in that VCAM-1 was expressed on HUVE up to 48 hours after continuous stimulation (Fig 3) , and bound lymphocytes but not neutrophils. Neutrophils do not bind to VCAM-1-transfected COS cells6 and lack VLA-4,20 the leukocyte receptor for VCAM-1.2'.22 VCAM-1 is similar to ICAM-1 in the duration of expression during continuous exposure to rhTNF-a (Fig 3) , rhIL-1, or LPS. However, several features distinguish VCAM-1 from ICAM-1. Surface expression of VCAM-1 appears to be more limited than ICAM-1. In these experiments VCAM-1 was detected only on HUVE, whereas ICAM-1 was found on cytokine-activated fibroblasts, smooth muscle cells, and k e r a t i n~c y t e s .~~.~~ ICAM-1 may also be a ligand for Mac-1 (CD 1 1 b/CD 18) as well as LFA-1, and is involved in adherence of neutrophils as well as lymphocytes to HUVE.25 However, VCAM-1 bound only mononuclear leukocytes. Finally, ICAM-1 is constituitively expressed on unstimulated HUVE, while VCAM-1 was absent, or minimally expressed, on unstimulated HUVE. Detectable levels of VCAM-1 on unstimulated HUVE were occasionally seen by ELISA, and a faint band was sometimes detected after immunoprecipitation of metabolically labeled, unstimulated HUVE. Also, the observation that MoAb 4B9 reduced adherence of lymphocytes to unstimulated HUVE indicates that VCAM-1 may be minimally expressed on unactivated HUVE. This low-level, constituitive expression of VCAM-1 on HUVE, however, may simply reflect activation by TNF-a or IL-1 released by residual mononuclear cells in early passage cultures.
The molecular cloning and sequencing of VCAM-1 predicts a 69-Kd core protein with six potential N-linked glycosylation sites that, if fully glycosylated, would yield a mature protein of 90 Kd.6 This is in general agreement with the metabolically labeled proteins that were immunoprecipitated by MoAb 4B9 with a major band at 100 Kd and a minor band at 92 Kd that were resolved to a single protein of 80 Kd after treatment with N-glycosidase. These estimated molecular weights are similar to inducible cell adhesion molecule-1 10 (INCAM-1 lo), a recently described endothelial protein that is involved in adhesion of melanoma cell lines.26 Because VCAM-1 also binds melanoma cells (Harlan JM, Kovach NL, unpublished observations, October 1989), it seems likely that INCAM-1 10 and VCAM-1 are the same protein.
In summary, we have generated an MoAb, 4B9, that recognizes a protein, VCAM-1, that is expressed on LPS-, rhTNF-, or rhIL-1-stimulated HUVE. VCAM-1 mediates a component of the adherence of PBL to rhTNF-stimulated HUVE. This CDl8-independent mechanism of lymphocyte adherence to cytokine-stimulated endothelium may be an important pathway of lymphocyte emigration at sites of inflammation and immune reactions.
